The Swiss Market Index concluded Monday's trading session 0.22% higher as investors assessed the implications of the US-Iran conflict, which further intensified over the weekend.
"The deteriorating situation in the Gulf and the rise in energy prices are supporting the dollar against the low-yielders, including the euro. Worryingly for Europe, natural gas prices are creeping higher again at a time of low inventories," analysts at ING said. "In the absence of direction from the [US Federal Reserve], higher energy prices will keep tightening fears alive and the dollar in demand."
Switzerland's economic news calendar was empty for the day, while Tuesday will see the release of the producer and import prices report for June. Market watchers are also awaiting the publication of the June US inflation figures and the UK's May gross domestic product, among other data releases across key economies.
On the corporate front, ABB (ABBN.SW) signed a multimillion, multiyear deal with India-based technology company Tata Consultancy Services, or TCS, expanding their collaboration. TCS will help the Switzerland-listed electrification and automation company improve user experience and operational efficiency, and bolster security and compliance. ABB's stock was up 0.29% at closing.
Deutsche Bank Research revised its rating on DocMorris (DOCM.SW) and increased the price target to 11.50 francs from 5.50 francs, noting that the Swiss online pharmacy's recent trading updates indicate accelerating revenue momentum. The stock jumped 17.25% on Monday's close.
"We upgrade DocMorris to Buy (from Hold) as we see an increasingly attractive risk/ reward profile driven by four factors: (1) likely upside to 2026 guidance, (2) reduced funding requirements, (3) a more favourable regulatory backdrop, and (4) the underappreciated value of TeleClinic," the research firm said in a note. "Following a period dominated by concerns over funding needs and execution risk, we believe the investment debate is shifting towards earnings growth, cash flow improvement and the monetisation of DocMorris' digital health ecosystem."